Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Plasma, an ionized gas composed of charged particles, has shown therapeutic potential in enhancing biological processes such as wound healing and tissue integration. Implants, such as silicone and human acellular dermal matrix (hADM), are commonly used in reconstructive surgery, but improving their biocompatibility and integration remains a challenge. This study investigated the effects of vacuum plasma treatment on silicone and hADM implants using an in vivo rat model. Plasma-treated and untreated implants were inserted subcutaneously, and tissue samples were collected at 1, 4, and 8 weeks post-implantation. Histological and immunohistochemical analyses were performed to assess inflammation, cellular infiltration, collagen formation (neocollagenesis), and angiogenesis. Results showed that plasma-treated silicone and hADM implants had significantly reduced capsule thickness at weeks 4 and 8 compared to untreated controls, indicating a lower chronic inflammatory response. Plasma treatment also promoted greater fibroblast infiltration and enhanced neocollagenesis within the hADM implants. Furthermore, immunohistochemical staining revealed a notable increase in blood vessel formation around and within the plasma-treated hADM implants, suggesting improved vascularization. In conclusion, vacuum plasma treatment enhances the biocompatibility and tissue integration of implants by reducing inflammation and promoting cellular and vascular responses, offering promising potential for improving outcomes in reconstructive surgery.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12193081PMC
http://dx.doi.org/10.3390/ijms26125854DOI Listing

Publication Analysis

Top Keywords

plasma treatment
16
hadm implants
16
tissue integration
12
vacuum plasma
12
reducing inflammation
8
silicone human
8
human acellular
8
acellular dermal
8
dermal matrix
8
implants
8

Similar Publications

Background: To review the biological functions of ergothioneine (ERGO), its correlation with plasma levels in cognitive frailty, and research progress in treating frailty and cognitive impairment, with the aim of providing a reference for ERGO application in cognitive frailty treatment.

Methods: A comprehensive review of existing literature on ERGO's chemical structure, sources, antioxidant and anti-inflammatory effects, and its role in cognitive frailty was conducted. Clinical trial data and metabolomic studies were also analyzed to understand ERGO's therapeutic potential.

View Article and Find Full Text PDF

The timely release of chemical messengers is a crucial step in cell-to-cell communication. Does this release occur as a passive diffusion from the donor membrane or it is actively regulated? A series of studies indicated that chemical messengers' secretion is "sub-quantal". This mode of secretion demands a strongly regulated release mechanism and calls for a thorough characterization of the release sites.

View Article and Find Full Text PDF

Dual-Mode Hybrid Discharge Plasma-Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy.

Adv Healthc Mater

September 2025

Department of Physics, Department of Materials Science and Engineering, and Department of Biomedical Engineering, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, China.

Although cold atmospheric plasma is a promising therapeutic technique for tumor immunotherapy via reactive oxygen and nitrogen species (RONS), the challenges associated with the generation and delivery of these RONS hamper clinical adoption. Herein, a dual-mode hybrid discharge plasma-activated sodium alginate hydrosols (PAH) is proposed to enhance the antitumor immune response. Gaseous highly reactive RONS are generated by dual-mode hybrid plasma produced by mixed O and NO modes, which are converted into aqueous RONS in PAH via gas-liquid reactions between plasma and hydrosols.

View Article and Find Full Text PDF

Hemophilia B gene therapy treatments currently have not addressed the need for predictable, durable, active, and redosable factor IX (FIX). Unlike conventional gene therapy, engineered B Cell Medicines (BCMs) are durable, redosable, and titratable, and thus have the potential to address significant unmet needs in the Hemophilia B treatment paradigm. BE-101 is an autologous BCM comprised of expanded and differentiated B lymphocyte lineage cells genetically engineered ex vivo to secrete FIX-Padua.

View Article and Find Full Text PDF

Background: Astaxanthin Z-isomers have attracted much attention because recent studies have demonstrated that they exhibit greater bioavailability and biological activity than the naturally predominant all-E-isomer. However, the plasma appearance and tissue distribution of astaxanthin isomers when administered with a diet rich in astaxanthin Z-isomers are largely unknown. To understand the health benefits and safety of astaxanthin Z-isomers, it is important to study the in vivo kinetics of the isomers.

View Article and Find Full Text PDF